Ferring Pharmaceuticals, the privately owned Swiss specialty biopharma group, has signed an agreement to acquire Gameto, a cell-engineering biotech focused on women’s reproductive health, in a deal valued at up to $1.3825B. The price is tied to development, regulatory, and commercial milestones, and closing remains subject to customary conditions. Until then, the two companies will operate independently. The deal would pair Gameto’s science with Ferring’s global reproductive-medicine footprint. Gameto’s In Vitro Maturation program is investigational in the U.S. and has not been approved by the FDA.
“This is a defining moment for Gameto and for our mission to transform reproductive health. By combining our pioneering cell-engineering platform with Ferring’s deep expertise and global reach in reproductive medicine, we have an extraordinary opportunity to accelerate innovation, expand access and bring more modern fertility treatment options to women and families around the world,” remarked Dr. Dina Turner, CEO and cofounder of Gameto.
This is a defining moment for Gameto and for our mission to transform reproductive health. By combining our pioneering cell-engineering platform with Ferring’s deep expertise and global reach in reproductive medicine, we have an extraordinary opportunity to accelerate innovation, expand access and bring more modern fertility treatment options to women and families around the world. – Dr. Dina Turner
Founded by Dr. Dina Radenkovic Turner and Martin Varsavsky, the founder of fertility clinic network Inception Prelude, Gameto has raised a total of $127M in reported equity funding. Its $44M Series C in August 2025 was led by Overwater Ventures, and its $33M Series B in May 2024 was led by Two Sigma Ventures with RA Capital Management. The company is also backed by Insight Partners, Future Ventures, BOLD Capital Partners, FJ Labs, Lux Capital, TA Ventures, Gaingels, Portfolia, YES VC, ICLUB VC, AmplifyHer Ventures, Plum Alley, Myelin VC, SALT Fund, Korify Capital, Ingeborg Investments, Arcadia Investment Partners, The Pags Group, Pontiva Healthcare Partners, and angels including Anne Wojcicki, Brian Armstrong, Jack Abraham, Robert Nelsen, Daniel Rosen, Chelsea M.R. Hirschhorn, and Stacey Bendet.
Gameto’s lead program, Fertilo, uses engineered cells to improve how eggs mature for IVF. It is already being used in clinics in Australia and Latin America, and a Phase 3 trial is underway in the U.S., with preliminary results expected in late 2026. Beyond fertility, the company is developing menopause therapies through its Ameno program, which has received funding from ARPA-H.
“Ferring has been committed to helping people build families for more than 50 years. By combining Gameto’s scientific innovation with our expertise and global reproductive-medicine platform, we see an opportunity to advance new approaches in fertility care and reach more patients worldwide,” remarked Jean-Frédéric Paulsen, Chairman of the Board of Directors and CEO of Ferring Pharmaceuticals.
Ferring has been committed to helping people build families for more than 50 years. By combining Gameto’s scientific innovation with our expertise and global reproductive-medicine platform, we see an opportunity to advance new approaches in fertility care and reach more patients worldwide. – Jean-Frédéric Paulsen
